Sinopharm Group Ltd. Overview
Get informed when a big investor buys or sells
+ Follow16.18%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for SHTDF is 16.18%. That is above the sector sector average of 11.64%. Investors often review this figure alongside Sinopharm Group Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against its sector companies, SHTDF currently prints 16.18% for ROE, while the sector average sits near 11.64%. That is roughly 39.1% above the sector mean. Large gaps often invite a closer look at Sinopharm Group Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively Sinopharm Group Ltd. converts resources into returns. At 16.18%, SHTDF may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting SHTDF's ROE (16.18%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
